(Bloomberg) -- Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies ...

Virat Kohli and Rohit Sharma came under fire Monday as India chewed over a 3-0 Test series home defeat to New Zealand, with critics calling the team ageing and low on confidence. The cricket ...

on its weight loss medicine VK2735 indicates that Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY), which currently dominate the obesity drug space, could face competition. VK2735, which is being ...

"Losing 3-0 at home is a tough pill to swallow and it calls for introspection," former skipper Sachin Tendulkar wrote on social media. "Was it lack of preparation, was it poor shot selection or ...

VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to treat obesity and other metabolic disorders. Viking plans to begin a ...

LONDON, Nov 4 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and ...

For India there is little time to fix things -- they travel to Australia for a five-match Test series starting on November 22. ‘Losing 3-0 at home is a tough pill to swallow and it calls for ...

Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill. The San Diego-based company’s stock ...

Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 ...